Phospho-eIF4G (Ser1108) Antibody [G15K10]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 IHC1:1000

Application
WB, IHC

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
175 kDa

Datasheet & SDS

Biological Description

Specificity
Phospho-eIF4G (Ser1108) Antibody [G15K10] detects endogenous levels of total eIF4G protein only when it is phosphorylated at Ser1108.

Clone
G15K10

Synonym(s)
Eukaryotic translation initiation factor 4 gamma 1, eIF-4-gamma 1; eIF-4G 1; eIF-4G1, p220, EIF4G1, EIF4F, EIF4G, EIF4GI

Background
Phospho‑eIF4G (Ser1108) corresponds to a serum‑regulated, mTOR‑sensitive phosphorylation state of the eukaryotic initiation factor 4G scaffold, which functions within the eIF4F complex to coordinate cap recognition, RNA helicase activity, and recruitment of mRNA to ribosomes, and which integrates growth factor and nutrient signaling into selective control of translation initiation. The eIF4G1 protein contains multiple modular regions that bind eIF4E at the mRNA cap, eIF4A helicase, eIF3 and the 40S ribosomal subunit, and regulatory factors such as 4E‑BPs; its C‑terminal region harbors several serum‑stimulated phosphorylation sites, including Ser1108, that respond to upstream kinase cascades. Phosphorylation at Ser1108 increases after activation of the PI3K–mTOR axis by ligands such as insulin‑like growth factor 1 and is blocked by the PI3K inhibitor LY294002 and by the mTOR/FRAP inhibitor rapamycin, placing this site under direct control of canonical growth and nutrient‑sensing pathways that also regulate p70S6K and 4E‑BP phosphorylation. Ser1108 phosphorylation associates with enhanced eIF4E–eIF4G interaction and activation of cap‑dependent translation, and the degree of phosphorylation at this site correlates with the assembly of active eIF4F complexes and with the translational status of growth‑related mRNAs that rely on efficient cap recognition and 5′‑UTR unwinding. MNK2, a MAPK‑interacting kinase activated by ERK and p38 MAPK, limits eIF4G Ser1108 phosphorylation through a negative regulatory pathway that impacts mTOR signaling: depletion of MNK2 increases Ser1108 phosphorylation and maintains this modification under conditions of rapamycin treatment, starvation, or muscle atrophy, whereas overexpression of MNK2 decreases Ser1108 phosphorylation and reduces p70S6K activation. This relationship defines MNK2 as a brake on mTOR‑dependent activation of eIF4G, establishing phospho‑eIF4G (Ser1108) as a convergence point between MAPK–MNK2 and PI3K–mTOR pathways in the fine‑tuning of translational capacity in skeletal muscle and other insulin‑responsive tissues. The same C‑terminal segment that contains Ser1108 also integrates additional regulatory phosphorylations, generating a combinatorial modification pattern that modulates eIF4A and eIF4B binding, eIF4F stability, and the efficiency of recruiting structured or weakly translated mRNAs, which links phospho‑eIF4G (Ser1108) to broader remodeling of initiation complex composition under anabolic conditions.

Background

Phospho‑eIF4G (Ser1108) corresponds to a serum‑regulated, mTOR‑sensitive phosphorylation state of the eukaryotic initiation factor 4G scaffold, which functions within the eIF4F complex to coordinate cap recognition, RNA helicase activity, and recruitment of mRNA to ribosomes, and which integrates growth factor and nutrient signaling into selective control of translation initiation. The eIF4G1 protein contains multiple modular regions that bind eIF4E at the mRNA cap, eIF4A helicase, eIF3 and the 40S ribosomal subunit, and regulatory factors such as 4E‑BPs; its C‑terminal region harbors several serum‑stimulated phosphorylation sites, including Ser1108, that respond to upstream kinase cascades. Phosphorylation at Ser1108 increases after activation of the PI3K–mTOR axis by ligands such as insulin‑like growth factor 1 and is blocked by the PI3K inhibitor LY294002 and by the mTOR/FRAP inhibitor rapamycin, placing this site under direct control of canonical growth and nutrient‑sensing pathways that also regulate p70S6K and 4E‑BP phosphorylation. Ser1108 phosphorylation associates with enhanced eIF4E–eIF4G interaction and activation of cap‑dependent translation, and the degree of phosphorylation at this site correlates with the assembly of active eIF4F complexes and with the translational status of growth‑related mRNAs that rely on efficient cap recognition and 5′‑UTR unwinding. MNK2, a MAPK‑interacting kinase activated by ERK and p38 MAPK, limits eIF4G Ser1108 phosphorylation through a negative regulatory pathway that impacts mTOR signaling: depletion of MNK2 increases Ser1108 phosphorylation and maintains this modification under conditions of rapamycin treatment, starvation, or muscle atrophy, whereas overexpression of MNK2 decreases Ser1108 phosphorylation and reduces p70S6K activation. This relationship defines MNK2 as a brake on mTOR‑dependent activation of eIF4G, establishing phospho‑eIF4G (Ser1108) as a convergence point between MAPK–MNK2 and PI3K–mTOR pathways in the fine‑tuning of translational capacity in skeletal muscle and other insulin‑responsive tissues. The same C‑terminal segment that contains Ser1108 also integrates additional regulatory phosphorylations, generating a combinatorial modification pattern that modulates eIF4A and eIF4B binding, eIF4F stability, and the efficiency of recruiting structured or weakly translated mRNAs, which links phospho‑eIF4G (Ser1108) to broader remodeling of initiation complex composition under anabolic conditions.

References
https://pubmed.ncbi.nlm.nih.gov/23105104/ https://pubmed.ncbi.nlm.nih.gov/22337810/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%